SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hellstrand M) "

Sökning: WFRF:(Hellstrand M)

  • Resultat 1-10 av 66
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Forte, A, et al. (författare)
  • c-Myc antisense oligonucleotides preserve smooth muscle differentiation and reduce negative remodelling following rat carotid arteriotomy
  • 2005
  • Ingår i: Journal of Vascular Research. - : S. Karger AG. - 1423-0135 .- 1018-1172. ; 42:3, s. 214-225
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: The vascular biology of restenosis is complex and not fully understood, thus explaining the lack of effective therapy for its prevention in clinical settings. The role of c-Myc in arteriotomy-induced stenosis, smooth muscle cell (SMC) differentiation and apoptosis was investigated in rat carotids applying full phosphorothioate antisense ( AS) oligonucleotides (ODNs). Methods: Carotid arteries from WKY rats were submitted to arteriotomy and to local application of ODNs through pluronic gel. Apoptosis ( deoxynucleotidyl transferase-mediated dUTP nick end-labelling), SMC differentiation (SM22 immunofluorescence) and vessel morphology and morphometry ( image analysis) were determined 2, 5 and 30 days after injury, respectively. Results: AS ODNs induced a 60% decrease of target c-Myc mRNA 4 h after surgery in comparison to control sense ( S) and scrambled ODN-treated carotids (p < 0.05). A significant 37 and 50% decrease in SM22 protein in the media of S ODN-treated and untreated carotids was detected when compared to uninjured contralateral arteries (p < 0.05). This reduction in SM22 expression was prevented in AS ODN-treated carotids. Stenosis was mainly due to adventitial constrictive remodelling. Lumen area in AS ODN-treated carotids was 35% greater than in control arteries 30 days after surgery (p < 0.05). TUNEL assay revealed increased apoptosis in AS ODN-treated carotids (p < 0.05). Conclusions: c-Myc AS ODNs reduce arteriotomy-induced negative remodelling. This is accompanied by maintained SMC differentiation and greater apoptosis. The combination of reduced c-Myc-induced proliferation and increased apoptosis may thus underlie the less severe remodelling upon treatment with c-Myc mRNA AS ODN.
  •  
3.
  • Kumar, B, et al. (författare)
  • Upregulated TRPC1 Channel in Vascular Injury In Vivo and Its Role in Human Neointimal Hyperplasia.
  • 2006
  • Ingår i: Circulation Research. - 0009-7330. ; 98:4, s. 557-563
  • Tidskriftsartikel (refereegranskat)abstract
    • Occlusive vascular disease is a widespread abnormality leading to lethal or debilitating outcomes such as myocardial infarction and stroke. It is part of atherosclerosis and is evoked by clinical procedures including angioplasty and grafting of saphenous vein in bypass surgery. A causative factor is the switch in smooth muscle cells to an invasive and proliferative mode, leading to neointimal hyperplasia. Here we reveal the importance to this process of TRPC1, a homolog of Drosophila transient receptor potential. Using 2 different in vivo models of vascular injury in rodents we show hyperplasic smooth muscle cells have upregulated TRPC1 associated with enhanced calcium entry and cell cycle activity. Neointimal smooth muscle cells after balloon angioplasty of pig coronary artery also express TRPC1. Furthermore, human vein samples obtained during coronary artery bypass graft surgery commonly exhibit an intimal structure containing smooth muscle cells that expressed more TRPC1 than the medial layer cells. Veins were organ cultured to allow growth of neointimal smooth muscle cells over a 2-week period. To explore the functional relevance of TRPC1, we used a specific E3-targeted antibody to TRPC1 and chemical blocker 2-aminoethoxydiphenyl borate. Both agents significantly reduced neointimal growth in human vein, as well as calcium entry and proliferation of smooth muscle cells in culture. The data suggest upregulated TRPC1 is a general feature of smooth muscle cells in occlusive vascular disease and that TRPC1 inhibitors have potential as protective agents against human vascular failure.
  •  
4.
  • Smith, E., et al. (författare)
  • Impact of a short-term Mediterranean diet intervention on plasma metabolites : a pilot study
  • 2024
  • Ingår i: Metabolomics. - 1573-3882. ; 20:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Dietary habits significantly influence the risks of type 2 diabetes and cardiovascular disease. Through metabolomics, we’ve previously measured plasma metabolites to gauge dietary quality, introducing a healthy dietary metabolic signature (HDMS) linked to a decreased risk of future type 2 diabetes and coronary artery disease. Objectives: To assess the impact of a 6-day dietary intervention on plasma metabolites and the HDMS. Methods: Fifty-nine Swedish participants (71% women, mean age 69 years) underwent a 6-day Mediterranean diet (MD) intervention in Italy’s Cilento region. All meals, crafted from local recipes and ingredients, were provided. Metabolite profiling pre- and post-intervention was conducted with a UHPLC-QTOF. Alterations in metabolite levels and the HDMS were examined using paired T-test. Results: The MD intervention notably enhanced the HDMS across participants (mean increase: 1.3 standard deviations (SD), 95% CI 1.1–1.4, p = 6E-25). Out of 109 metabolites, 66 exhibited significant alterations (fdr adjusted p < 0.05). Among the 10 most significant changes, increases were observed in several diet related metabolites such as pipecolate, hippurate, caffeine, homostachydrine, acylcarnitine C11:0, acetylornithine, beta-carotene and 7-methylguanine. The most significant decreases manifested in piperine and 3-methylhistidine. Conclusions: The HDMS, which is linked to a healthy diet and inversely associated with cardiometabolic disease, was significantly improved by the 6-day Mediterranean diet intervention. Notably, metabolite markers previously shown to be indicative of the intake of vegetables, fruits, grains, and legumes increased, while markers previously associated with red meat consumption decreased. These findings highlight the potential of short-term dietary interventions to induce significant changes in plasma metabolite profiles.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • Alsiö, Åsa, 1965, et al. (författare)
  • Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection
  • 2012
  • Ingår i: European Journal of Clinical Microbiology & Infectious Diseases. - : Springer Science and Business Media LLC. - 0934-9723 .- 1435-4373. ; 31:7, s. 1631-1635
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of the present study was to evaluate the utility of hepatitis C virus (HCV) core antigen (coreAg) assessment for the identification of candidates for short-term therapy. Plasma samples from HCV genotype 2 or 3-infected patients participating in the NORDynamIC trial (n = 382) comparing 12 and 24 weeks of combination treatment with pegylated interferon-alpha 2a and a fixed dose of 800 mg ribavirin daily were analyzed for coreAg. Among the 126 patients (33% of the intention-to-treat population) achieving HCV coreAg levels in plasma below 0.2 pg/mL when assayed on treatment day 3, sustained viral response (SVR) rates of 86% and 84% were achieved in the 12- and 24-week arms, respectively. Similarly, among patients having received at least 80% of the target dose of both pegylated interferon alpha-2a and of ribavirin for at least 80% of the target treatment duration (per-protocol analysis), the SVR rates were 89% and 95%, respectively. Twelve weeks of combination treatment may be sufficient for genotype 2 or 3-infected patients achieving HCV coreAg levels below 0.2 pg/mL by day 3, signaling a rapid clearance of HCV viremia.
  •  
9.
  •  
10.
  • Cohen, Samuel I. A., et al. (författare)
  • Proliferation of amyloid-beta 42 aggregates occurs through a secondary nucleation mechanism
  • 2013
  • Ingår i: Proceedings of the National Academy of Sciences. - : Proceedings of the National Academy of Sciences. - 1091-6490 .- 0027-8424. ; 110:24, s. 9758-9763
  • Tidskriftsartikel (refereegranskat)abstract
    • The generation of toxic oligomers during the aggregation of the amyloid-beta (A beta) peptide A beta 42 into amyloid fibrils and plaques has emerged as a central feature of the onset and progression of Alzheimer's disease, but the molecular pathways that control pathological aggregation have proved challenging to identify. Here, we use a combination of kinetic studies, selective radiolabeling experiments, and cell viability assays to detect directly the rates of formation of both fibrils and oligomers and the resulting cytotoxic effects. Our results show that once a small but critical concentration of amyloid fibrils has accumulated, the toxic oligomeric species are predominantly formed from monomeric peptide molecules through a fibril-catalyzed secondary nucleation reaction, rather than through a classical mechanism of homogeneous primary nucleation. This catalytic mechanism couples together the growth of insoluble amyloid fibrils and the generation of diffusible oligomeric aggregates that are implicated as neurotoxic agents in Alzheimer's disease. These results reveal that the aggregation of A beta 42 is promoted by a positive feedback loop that originates from the interactions between the monomeric and fibrillar forms of this peptide. Our findings bring together the main molecular species implicated in the A beta aggregation cascade and suggest that perturbation of the secondary nucleation pathway identified in this study could be an effective strategy to control the proliferation of neurotoxic A beta 42 oligomers.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 66
Typ av publikation
tidskriftsartikel (48)
konferensbidrag (16)
bokkapitel (2)
Typ av innehåll
refereegranskat (48)
övrigt vetenskapligt/konstnärligt (18)
Författare/redaktör
Hellstrand, Per (16)
Landen, M (13)
Hellstrand, Kristoff ... (13)
Eriksson, E (13)
Melke, J (9)
Hellstrand, Sophie (8)
visa fler...
Ericson, Ulrika (8)
Orho-Melander, Marju (8)
Lagging, Martin, 196 ... (8)
Nilsson, Peter M (7)
Lydrup, M-L (7)
Baghaei, F (6)
Swärd, Karl (5)
Rosmond, R (5)
Holm, G (5)
Martner, Anna, 1979 (5)
Norkrans, Gunnar, 19 ... (5)
Westin, Johan, 1965 (5)
Nilsson, Staffan, 19 ... (4)
Brune, M (4)
Linse, Sara (4)
Melander, Olle (4)
Hellstrand, Erik (4)
Waldenström, Jesper, ... (4)
Sonestedt, Emily (4)
Langeland, N. (4)
Engström, Gunnar (3)
Dobson, Christopher ... (3)
Farkkila, M (3)
Brune, Mats, 1950 (3)
Bergh Thorén, Fredri ... (3)
Albinsson, Sebastian (3)
Lindh, Magnus, 1960 (3)
Buhl, M. R. (3)
Jansson, M. (2)
Drake, Isabel (2)
Christensen, P (2)
Söderholm, Jonas, 19 ... (2)
Nilsson, Bengt-Olof (2)
Aurelius, Johan, 198 ... (2)
Törnell, Andreas, 19 ... (2)
Arabpour, Mohammad (2)
Grauers Wiktorin, Ha ... (2)
Hultgårdh, Anna (2)
PEDERSEN, C (2)
Nordström, Ina (2)
Bhattachariya, Anirb ... (2)
Mellqvist, UH (2)
Morch, K. (2)
Gullberg, Bo (2)
visa färre...
Lärosäte
Lunds universitet (32)
Karolinska Institutet (18)
Göteborgs universitet (14)
Chalmers tekniska högskola (3)
Uppsala universitet (2)
Umeå universitet (1)
visa fler...
Nordiska Afrikainstitutet (1)
Stockholms universitet (1)
Mälardalens universitet (1)
Malmö universitet (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (66)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (41)
Naturvetenskap (4)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy